These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37414584)

  • 1. S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8
    Li H; Chen J; Li Z; Chen M; Ou Z; Mo M; Wang R; Tong S; Liu P; Cai Z; Zhang C; Liu Z; Deng D; Liu J; Cheng C; Hu J; Zu X
    Adv Sci (Weinh); 2023 Sep; 10(25):e2300110. PubMed ID: 37414584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8
    Yu A; Hu J; Fu L; Huang G; Deng D; Zhang M; Wang Y; Shu G; Jing L; Li H; Chen X; Yang T; Wei J; Chen Z; Zu X; Luo J
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
    Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
    Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
    Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
    BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity.
    Cai Z; Chen J; Yu Z; Li H; Liu Z; Deng D; Liu J; Chen C; Zhang C; Ou Z; Chen M; Hu J; Zu X
    Adv Sci (Weinh); 2023 Mar; 10(8):e2207155. PubMed ID: 36642843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8
    Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
    Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8
    Xia W; Zhang S; Duan H; Wang C; Qian S; Shen H
    Med Oncol; 2022 Jan; 39(3):37. PubMed ID: 35059863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.
    Jia X; Zhang D; Zhou C; Yan Z; Jiang Z; Xie L; Jiang J
    Front Oncol; 2023; 13():1175183. PubMed ID: 37637034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
    Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
    Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EIF4A3 serves as a prognostic and immunosuppressive microenvironment factor and inhibits cell apoptosis in bladder cancer.
    Hu B; Chen R; Jiang M; Xiong S; Liu X; Fu B
    PeerJ; 2023; 11():e15309. PubMed ID: 37180585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
    Chen S; Zhang N; Shao J; Wang T; Wang X
    J Cancer; 2019; 10(3):697-707. PubMed ID: 30719168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.